Receive news by e-mail

#
 

Enter your e-mail in the field below to receive directly the news that appears on this page.

 

topics : related - all Explore

Shopping

Top Product

Bodies, Commodities, and Biotechnologies: Death, Mourning, and Scientific Desire in the Realm of Human Organ Transfer (Leonard Hastings Schoff Lectures)

Compare prices

  1. 2. Nature's Operating Instructions: The True Biotechnologies (Bioneers Series)
  2. 3. Biotechnologies and International Human Rights (Studies in International Law)
  3. 4. Bodies, Commodities, and Biotechnologies: Death, Mourning, and Scientific Desire in the Realm of Human Organ Transfer (Leonard Hastings Schoff Lectures)
  4. 5. Crossing Over: Exchanges in Art and Biotechnologies

Shopping Categories

  1. 1. Mobile Phones
  2. 2. Digital Cameras
  3. 3. Smartphones
  4. 4. Laptop Computers
  5. 5. Graphics Cards
  6. 6. LCD TVs
  7. 7. LCD Monitors
  8. 8. Fridges
  9. 9. Vacuum Cleaners
  10. 10. Freezers
  11. 11. Washing Machines
  12. 12. Microwaves
  13. 13. Electric Kettles
  14. 14. Digital Camcorders
  15. 15. Dishwashers

Wikio Shopping

  1. 1. Baby & Nursery
  2. 2. Books
  3. 3. Car/Motorbike
  4. 4. CD
  5. 5. Communication
  6. 6. Computers
  7. 7. DVD
  8. 8. Electronics
  9. 9. Entertainment
  10. 10. Fashion & Lingerie
  11. 11. Finance
  12. 12. Gifts & Gadgets
  13. 13. Health & Beauty
  14. 14. Home & Garden
  15. 15. Hotels
  16. 16. Household Appliances
  17. 17. Sport & Fitness
  18. 18. Travel
  19. 19. Video Games

Participate



Biotechnologies



Sort by : relevance - date - popularity
+Vote!

Theravance, Inc.: Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia

SOUTH SAN FRANCISCO, CA (MARKET WIRE) Theravance, Inc. (NASDAQ: THRX) announced today that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) related to the telavancin New Drug Application (NDA) for the treatment of nosocomial pneumonia (NP). Telavancin is a bactericidal, once-daily injectable investigational antibiotic for the treatment of NP caused by Gram-positive...

+Vote!

Was is "Worst Biotech CEO" Worth?

Recently, we posted about misadventures of the leadership of biotechnology giant Genzyme. Although the company has long priced its drug Cerezyme for the rare Gaucher's disease at a stratospheric level, it did not sufficiently reinvest money in its manufacturing facility for the drug. Deferred maintenance at a production facility running at maximum capacity has apparently lead to two different kinds...

+Vote!

Pre Market Stock Gainers & Losers - 11/27/09

Below is a list of some of the largest stock gainers and losers so far in pre market for November 27, 2009. Check out my Hot Stocks to Watch page for the latest updates. Pre Market Stock Gainers - 11/27/09 Direxion Daily Emrg Mkts Bear 3X Shares (EDZ) Direxion Daily Small Cap Bear 3X Shares (TZA) UltraShort FTSE/Xinhua China25 Proshares (FXP) Direxion Daily Financial Bear 3X Shares (FAZ) UltraShort...

3Vote!

The Fortune Financial: The Fortune Financial Undertakes Review of Stocks in the Healthcare and Services Sectors

NEW DELHI, INDIA (MARKET WIRE) US markets declined but ended off their lows on Tuesday after the Federal Reserve raised its forecast for 2010. Fed minutes indicated that Federal Reserve officials are confident the US economic recovery will be durable, but do not see employment or inflation picking up soon. Today, we, at The Fortune Financial, have asked some of the top analysts worldwide to give us...

3Vote!

Why Some Vaccines May Require A Booster

[NEWS] ROCHESTER, N.Y., Nov. 27 /PRNewswire-USNewswire/ — Preventing disease is the goal of every health care provider and fortunately every year, new vaccines are being added to assist in disease prevention. But do all vaccines boost immunity for the same period of time? And, if not, when are additional 'booster shots' needed to keep immunity strong? In this month's issue of Pediatrics, the...

+Vote!

Largest Stock Losers - 11/27/09

November 27, 2009 - Below is a list of the Top 15 biggest losing stocks today that have decent volume. These stocks are usually going down on bad news. I usually throw these on my watch list and monitor them for a bounce or a potential short trade. Biggest Stock Losers - 11/27/09 1. PDL BioPharma, Inc. (PDLI) - News 2. ING GROUP NV ADS (ING) - News 3. Synta Pharmaceuticals Corp. (SNTA) - No News 4....

+Vote!

Acuo Technologies Announces Patent for Asset Communication Format Within a Computer Network

BLOOMINGTON, Minn, Nov. 27 /PRNewswire/ -- ACUO TECHNOLOGIES, developers of high-performance medical image management software, data migration tools and services, is pleased to announce that the United States Patent and Trademark Office has approved a patent application for an "Asset Communication Format within a Computer Network." Acuo Technologies is pleased to add the U.S. patent to its...

+Vote!

Turkey Day Workers Lead Fight Against H1N1

At one Philadelphia workplace this Thanksgiving, the talk is all pig, no turkey. Few people know, but the front line in the fight against the Swine Flu pandemic is inside a plain looking warehouse in Northeast Philadelphia. Home to MedImmune, a division of Astra Zeneca, workers there produce every single dose of swine flu mist vaccine administered across the country.

3Vote!

Cancer drug may treat diabetes

I've posted before about my brother Mark Pescovitz's fine art photography. In his spare time, Mark is a transplant surgeon and medical research scientist. Today, he and his colleagues published a paper in the New England Journal of Medicine about a new way to slow and possibly even stop the progression of type 1 diabetes, also known as juvenile-onset diabetes. The approach uses the drug Rituxan, normally...

3Vote!

Health Canada: Health Canada/Information Update: Foreign Particles Found in Certain Products From Genzyme

OTTAWA, ONTARIO (MARKET WIRE) Health Canada is informing health care professionals and Canadians that routine quality control testing has discovered foreign particles in a small number of vials of five products filled at a Genzyme Corporation facility in Boston. Genzyme has also received customer reports of foreign particles in some vials of these products. The particles observed include non-latex...

+Vote!

Knockouts in human cells point to pathogenic targets

[NEWS] Contact: Nicole Giese giese@wi.mit.edu 617-258-6851 Whitehead Institute for Biomedical Research CAMBRIDGE, Mass. (November 26, 2009) - Whitehead researchers have developed a new type of genetic screen for human cells to pinpoint specific genes and proteins used by pathogens, according to their paper in Science. In mos…

3Vote!

Nanowires key to future transistors, electronics

[NEWS] Contact: Emil Venere venere@purdue.edu 765-494-4709 Purdue University WEST LAFAYETTE, Ind. - A new generation of ultrasmall transistors and more powerful computer chips using tiny structures called semiconducting nanowires are closer to reality after a key discovery by researchers at IBM, Purdue University and the University of California at Lo…

3Vote!

First-ever blueprint of a minimal cell is more complex than expected

[NEWS] Contact: Sonia Furtado sonia.furtado@embl.de European Molecular Biology Laboratory EMBL and CRG scientists reveal what a self-sufficient cell can't do without Heidelberg, 27 November 2009 - What are the bare essentials of life, the indispensable ingredients required to produce a cell that can survive on its own? Can we…

3Vote!

Galapagos receives EUREKA innovation label and OSEO funding

MECHELEN, BELGIUM -- 11/26/09 -- Mechelen, Belgium; 26 November 2009 - Galapagos NV (Euronext: GLPG) announces that its antibody therapeutics program with MorphoSys and SARM program have been awarded funding by the French gove..

3Vote!

Senators And Representatives Get Paid To Talk, But Do We Always Know Who Is Paying Them?

These legislators make lots of speeches and ask questions at congressional hearings. That is part of their job and maybe they like doing that sort of thing (which might explain why they ran for office in the first place). So you might assume that the taxpayers are paying them to talk. But maybe not. The New York Times had an article recently called In House, Many Spoke With One Voice: Lobbyists’...